Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 3/20 | 0.50 |
| ▸ | FEN1 | P39748 | 3/20 | 0.50 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.50 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12432516 | 0.87 | ERCC1 (0.49) | ERCC1FEN1ERCC4RNASEH1NPSR1 | |
| SCHEMBL17749053 | 0.86 | ERCC1 (0.48) | ERCC1FEN1ERCC4RNASEH1NPSR1 | |
| SCHEMBL18832068 | 0.78 | ERCC1 (0.55) | ERCC1FEN1ERCC4RNASEH1NPSR1 | |
| SCHEMBL15069797 | 0.77 | KCNE1 (0.41) | ERCC1FEN1ERCC4RNASEH1 | |
| SCHEMBL12697348 | 0.74 | ERCC1 (0.57) | ERCC1FEN1ERCC4RNASEH1NPSR1 | |
| SCHEMBL8267930 | 0.74 | RNASEH1 (0.56) | ERCC1FEN1ERCC4RNASEH1ALDH1A1 | |
| SCHEMBL13041238 | 0.71 | NPSR1 (0.42) | ERCC1FEN1ERCC4RNASEH1NPSR1 | |
| SCHEMBL13041261 | 0.71 | ERCC1 (0.57) | ERCC1FEN1ERCC4 | |
| SCHEMBL5485304 | 0.71 | KDM4E (0.42) | ERCC1FEN1ERCC4RNASEH1KDM4E | |
| SCHEMBL13302558 | 0.70 | RNASEH1 (0.53) | ERCC1FEN1ERCC4RNASEH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8852632-B2 | Pharmaceutical formulation containing a release rate controlling composition | MERCK SHARP & DOHME CORP. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8357798-B2 | Process for preparing N-alkylated hydroxypyrimidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20100280244-A1 | PROCESS FOR PREPARING N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100249410-A1 | PROCESS FOR PREPARING N-ALKYLATED HYDROXYPYRIMIDINONE COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-09-30 | — | — | US | disclosed |
| US-7754731-B2 | Potassium salt of an HIV integrase inhibitor | MERCK SHARP & DOHME CORP. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20070292504-A1 | Pharmaceutical formulation containing a release rate controlling composition | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070259894-A1 | Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1 | MERCK SHARP & DOHME CORP. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280244-A1 | PROCESS FOR PREPARING N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDES | ALKBH3, DTYMK, DUT | ERCC1 3412/4885FEN1 863/4885ERCC4 3052/4885 |
| US-20070259894-A1 | Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1 | UGT1A1, UGT1A3, UGT1A9 | ERCC1 1640/4885FEN1 241/4885ERCC4 897/4885 |
| US-20100249410-A1 | PROCESS FOR PREPARING N-ALKYLATED HYDROXYPYRIMIDINONE COMPOUNDS | IMPA1, KCNJ1, KCNJ11 | ERCC1 1359/4885FEN1 261/4885ERCC4 749/4885 |
| US-20070292504-A1 | Pharmaceutical formulation containing a release rate controlling composition | REV1, POLR2H, POLR2E | ERCC1 1212/4885FEN1 663/4885ERCC4 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.